Profile data is unavailable for this security.
About the company
Gerresheimer AG is a Germany-based company that is active in the pharmaceuticals and health care industry. It operates through two business segments: Plastics and Devices, and Primary Packaging Glass. The Plastics and Devices segment produces standard and customized products for drug delivery, such as insulin pens, inhalers, and prefillable syrings. The Primary Packaging Glass segment focuses on the production of packaging of glass for medicines and cosmetics, such as pharmaceuticals jars, ampoules, injection vials, cartridges, perfume flacons and cream jars, as well as glass containers for the food and beverage industry. The Company operates approximately 40 production facilities in Europe, North America, South America and Asia.
- Revenue in EUR (TTM)2.01bn
- Net income in EUR114.30m
- Incorporated2007
- Employees12.01k
- LocationGerresheimer AGKlaus-Bungert-Strasse 4DUESSELDORF 40468GermanyDEU
- Phone+49 211618100
- Fax+49 2 116181295
- Websitehttps://www.gerresheimer.com/
More ▼
Mergers & acquisitions
| Acquired company | GXIX:GER since announced | Transaction value |
|---|---|---|
| Blitz LuxCo SARL | -20.76% | 865.68m |
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AddLife AB | 864.18m | 10.10m | 1.34bn | 2.36k | 137.17 | 3.13 | 14.79 | 1.55 | 0.9601 | 0.9601 | 82.16 | 42.09 | 0.7625 | 3.50 | 5.58 | 4,351,152.00 | 0.9063 | 5.31 | 1.29 | 8.83 | 37.30 | 36.89 | 1.19 | 5.79 | 0.638 | 1.66 | 0.5146 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| Oxford Nanopore Technologies PLC | 201.61m | -191.17m | 1.41bn | 1.28k | -- | 1.85 | -- | 6.98 | -0.187 | -0.187 | 0.197 | 0.662 | 0.2265 | 0.7333 | 2.86 | 135,499.20 | -21.47 | -21.12 | -24.63 | -24.67 | 53.89 | 53.90 | -94.82 | -81.85 | 3.36 | -- | 0.0747 | -- | -14.57 | 39.15 | -69.74 | -- | 8.92 | -- |
| SKAN Group AG | 370.39m | 34.71m | 1.73bn | 1.42k | 49.96 | 9.26 | 34.58 | 4.66 | 1.43 | 1.43 | 15.24 | 7.70 | 0.9179 | 0.6845 | 12.01 | 247,846.50 | 9.03 | 7.56 | 18.78 | 14.95 | 74.07 | 73.24 | 9.84 | 9.63 | 0.5813 | 38.46 | 0.0341 | 24.09 | 15.55 | 118.77 | 38.59 | 35.49 | -- | -- |
| Elekta AB (publ) | 1.56bn | 97.79m | 1.97bn | 4.57k | 20.86 | 2.21 | 9.87 | 1.26 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
| Embla Medical hf | 802.18m | 65.93m | 2.09bn | 4.00k | 31.98 | 2.80 | 17.76 | 2.61 | 1.14 | 1.14 | 13.87 | 13.06 | 0.5755 | 2.23 | 6.65 | 1,496,136.00 | 4.75 | 4.06 | 5.51 | 4.76 | 62.02 | 62.47 | 8.25 | 6.91 | 1.26 | 6.59 | 0.4074 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Medacta Group SA | 544.08m | 56.19m | 2.33bn | 1.83k | 41.33 | 6.74 | 19.63 | 4.27 | 2.61 | 2.61 | 25.29 | 16.01 | 0.7908 | 0.85 | 5.62 | 292,098.40 | 8.17 | 7.89 | 10.36 | 10.57 | 67.93 | 70.43 | 10.33 | 10.09 | 0.845 | 11.02 | 0.4015 | 17.01 | 16.85 | 13.38 | 2.41 | 0.6937 | 8.32 | -- |
| Gerresheimer AG | 2.01bn | 114.30m | 2.43bn | 12.01k | 21.29 | 1.70 | 7.83 | 1.21 | 3.31 | 3.31 | 58.26 | 41.47 | 0.5816 | 3.93 | 6.93 | 172,572.90 | 3.36 | 3.31 | 4.60 | 4.75 | 29.09 | 29.72 | 5.78 | 5.94 | 0.4635 | 4.29 | 0.4634 | 42.68 | 9.54 | 7.79 | 20.81 | 9.00 | 23.42 | 1.68 |
| Vitrolife AB | 306.76m | -328.43m | 2.49bn | 1.10k | -- | 2.19 | -- | 8.11 | -28.10 | -28.10 | 26.24 | 97.03 | 0.1867 | 3.48 | 6.48 | 3,293,791.00 | -19.99 | -4.57 | -20.71 | -4.78 | 58.16 | 58.38 | -107.03 | -21.89 | 2.36 | 9.24 | 0.135 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Ambu A/S | 722.80m | 31.51m | 3.49bn | 5.20k | 125.41 | 5.28 | 27.98 | 4.83 | 0.8839 | 0.8839 | 20.26 | 21.00 | 0.7694 | 2.21 | 7.14 | 1,037,529.00 | 3.35 | 3.22 | 3.91 | 3.87 | 59.38 | 59.54 | 4.36 | 4.43 | 1.47 | 58.64 | 0.0907 | 25.41 | 12.90 | 13.84 | 39.88 | -5.81 | 2.06 | 0.00 |
| Getinge AB | 2.90bn | 145.96m | 3.63bn | 11.85k | 26.63 | 1.49 | 11.43 | 1.25 | 6.21 | 6.21 | 123.33 | 111.09 | 0.5937 | 2.51 | 7.30 | 2,861,487.00 | 3.01 | 5.31 | 4.00 | 6.98 | 45.80 | 47.83 | 5.07 | 8.69 | 0.5965 | 10.34 | 0.2629 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
Data as of Nov 22 2024. Currency figures normalised to Gerresheimer AG's reporting currency: Euro EUR
